Avalo Therapeutics(AVTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates • Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024 • Appointed Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief Legal Officer • Cash on hand of approximately $93.4 million as of June 30, 2024 with expected cash runway into 2027 WAYNE, PA AND ROCKVILLE, MD, August 12, 2024 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today annou ...